Morphometrics predicts overall survival in patients with multiple myeloma spine metastasis: A retrospective cohort study
- PMID: 30210905
- PMCID: PMC6122282
- DOI: 10.4103/sni.sni_383_17
Morphometrics predicts overall survival in patients with multiple myeloma spine metastasis: A retrospective cohort study
Erratum in
-
Erratum: Morphometrics predicts overall survival in patients with multiple myeloma spine metastasis: A retrospective cohort study.Surg Neurol Int. 2018 Oct 8;9:204. doi: 10.4103/2152-7806.242957. eCollection 2018. Surg Neurol Int. 2018. PMID: 30386674 Free PMC article.
Abstract
Background: Treatment strategies for spinal metastases for myeloma range from conservative measures (radiation and chemotherapy) to invasive (surgical). Identifying better predictors of overall survival (OS) would help in surgical decision making. Analytic morphometrics has been shown to predict survival in oncologic patients, and our study evaluates whether morphometrics is predictive of survival in patients with multiple myeloma (MM) spinal metastases.
Methods: For this observational retrospective cohort study, we identified 46 patients with MM spinal metastases who had undergone stereotactic body radiation therapy. OS was the primary outcome measure. Morphometric analysis of the psoas muscle was performed using computed tomography scans of the lumbar spine.
Results: OS was statistically correlated with age (P = 0.025), tumor burden (P = 0.023), and number of levels radiated (P = 0.029), but not with gender. Patients in the lowest tertile of average psoas size had significantly shorter survival compared to the highest tertile, hazard ratio (HZ) 6.87 (95% CI = 1.65-28.5, P = 0.008). When calculating the psoas size to vertebral body ratio and correlating this measure to OS, the lowest tertile again had significantly shorter OS compared to the highest tertile, HZ 6.87 (95% CI = 1.57-29.89, P = 0.010); the middle tertile also showed significantly shorter OS compared to the highest tertile, HZ 5.07 (95% CI = 1.34-19.10, P = 0.016). Kaplan-Meier survival curves were used to visually illustrate the differences in survival between different tertiles (Log-rank test P = 0.006).
Conclusions: Morphometric analysis successfully predicts long-term survival in patients with MM. More research is needed to validate these results and to see if these methodologies can be applied to other cancer histologies.
Keywords: Frailty index; morphometric analysis; multiple myeloma mortality; oncologic outcomes; spinal metastases.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Application of morphometrics as a predictor for survival in female patients with breast cancer spinal metastasis: a retrospective cohort study.Spine J. 2018 Oct;18(10):1798-1803. doi: 10.1016/j.spinee.2018.03.007. Epub 2018 Mar 14. Spine J. 2018. PMID: 29550605
-
Application of morphometric analysis to patients with lung cancer metastasis to the spine: a clinical study.Neurosurg Focus. 2016 Aug;41(2):E12. doi: 10.3171/2016.5.FOCUS16152. Neurosurg Focus. 2016. PMID: 27476836
-
Sarcopenia Predicts Overall Survival in Patients with Lung, Breast, Prostate, or Myeloma Spine Metastases Undergoing Stereotactic Body Radiation Therapy (SBRT), Independent of Histology.Neurosurgery. 2020 May 1;86(5):705-716. doi: 10.1093/neuros/nyz216. Neurosurgery. 2020. PMID: 31232439
-
Application of Morphometrics as a Predictor for Survival in Patients with Prostate Cancer Metastasis to the Spine.World Neurosurg. 2018 Jun;114:e913-e919. doi: 10.1016/j.wneu.2018.03.115. Epub 2018 Mar 23. World Neurosurg. 2018. PMID: 29581018
-
Sarcopenia as a Prognostic Factor for 90-Day and Overall Mortality in Patients Undergoing Spine Surgery for Metastatic Tumors: A Multicenter Retrospective Cohort Study.Neurosurgery. 2020 Oct 15;87(5):1025-1036. doi: 10.1093/neuros/nyaa245. Neurosurgery. 2020. PMID: 32592483
Cited by
-
Sarcopenia in Patients With Spinal Metastasis: A Systematic Review and Meta-Analysis of Retrospective Cohort Studies.Front Oncol. 2022 Apr 5;12:864501. doi: 10.3389/fonc.2022.864501. eCollection 2022. Front Oncol. 2022. PMID: 35480101 Free PMC article.
-
Erratum: Morphometrics predicts overall survival in patients with multiple myeloma spine metastasis: A retrospective cohort study.Surg Neurol Int. 2018 Oct 8;9:204. doi: 10.4103/2152-7806.242957. eCollection 2018. Surg Neurol Int. 2018. PMID: 30386674 Free PMC article.
-
Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.Bone Marrow Transplant. 2021 Jan;56(1):225-231. doi: 10.1038/s41409-020-01008-9. Epub 2020 Jul 30. Bone Marrow Transplant. 2021. PMID: 32732941 Free PMC article.
-
Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1084-1093. doi: 10.1002/jcsm.13446. Epub 2024 Apr 1. J Cachexia Sarcopenia Muscle. 2024. PMID: 38558541 Free PMC article.
References
-
- Amelot A, Cristini J, Salaud C, Moles A, Hamel O, Moreau P, et al. Overall survival in spine myeloma metastases: Difficulties in predicting with prognostic scores. Spine. 2017;42:400–6. - PubMed
-
- Amelot A, Moles A, Cristini J, Salaud C, Touzeau C, Hamel O, et al. Predictors of survival in patients with surgical spine multiple myeloma metastases. Surg Oncol. 2016;25:178–83. - PubMed
-
- Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Living with advanced but stable multiple myeloma: A study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage. 2013;46:671–80. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources